Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Understand the scenarios where a cash back credit card is the best choice. Make your spending count with this guide.
26,647 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
JPMorgan trimmed its price target on Advance Auto Parts to $59 from $64, citing tax stimulus as a partial offset to h...
Kenya's High Court halted a U.S. plan to establish a quarantine facility for Americans exposed to Ebola, delaying a $...
A Gen Z hiring manager recounts a disruptive interview moment that sparks a broader debate over professionalism and e...
In a live Fox Business showdown, Peter Schiff and Anthony Pompliano spar over Bitcoin's future. Schiff questions intr...
Micron Technology stunned investors with an earnings beat and an ultra-high gross margin, suggesting it is riding an ...
As July 16 approaches, investors are weighing TSMC's Q2 results and what they mean for the stock. This article breaks...
A triple-leveraged ETF focused on semiconductors can swing wildly. This piece breaks down why the direxion daily semi...
Goldman Sachs flags four tech, media, and telecom bets on its Conviction List, each carrying 40% to 100% upside to ta...
Oil markets move on Middle East tensions as Iran squeezing U.S. supply tightens crude and lifts pump prices. American...
Toncoin and MemeCore surged roughly 30% as Bitcoin touched $81,000, signaling renewed trader interest amid a choppy m...
Solana stands at a turning point as SOL tests a key price band. Traders are watching resistance near the $100 mark an...